James Cochran
Urology · Dallas, TXNPI 1174577704
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. Profound Medical Corp. accounts for 68.6% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $2,264, 6.1 times the $374 reported in 2019.
Across 99 payments — averaging $58.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Profound Medical Corp.$4K
- Astellas Pharma US Inc$250
- AbbVie$179
- Myovant Sciences Inc.$172
- Merck$111
- Dendreon Pharmaceuticals LLC$111
- plus $998 from 23 others
Across 142 payments — averaging $7964.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$640K
- Bayer$127K
- Astellas Pharma Global Development$87K
- Urovant Sciences Inc$77K
- AbbVie$60K
- Pfizer$33K
- plus $106K from 8 others
What the payments were for
- Travel & lodging$2,50443%
- Food & beverage$3,18955%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Profound Medical Corp. | 11 | $3,986 |
| Astellas Pharma US Inc | 11 | $250 |
| AbbVie | 9 | $179 |
| Myovant Sciences Inc. | 8 | $172 |
| Merck | 5 | $111 |
| Dendreon Pharmaceuticals LLC | 6 | $111 |
| Pfizer | 6 | $104 |
| Johnson & Johnson(2 entities) | 3 | $76 |
| Innovation Technologies Inc | 2 | $73 |
| Urogen Pharma, Inc. | 3 | $67 |
| Novartis | 2 | $62 |
| Antares Pharma, Inc. | 3 | $57 |
| Progenics Pharmaceuticals, Inc. | 2 | $53 |
| Bayer | 3 | $52 |
| Blue Earth Diagnostics | 3 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Urovant Sciences Inc | 2 | $42 |
| Cook Medical LLC | 2 | $39 |
| Rochester Medical Corporation | 2 | $39 |
| Accord Healthcare, Inc. | 2 | $37 |
| Boston Scientific | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Amgen | 2 | $31 |
| Biotissue Holdings Inc. | 1 | $30 |
| Tolmar, Inc. | 1 | $19 |
| Coloplast | 1 | $15 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Laborie Medical Technologies Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tulsa-Pro$3,799
How this compares
$5,807 in reported general payments places this provider in the 60th percentile of 878 urology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 44 | $376 |
| Ciprofloxacin Hcl | 25 | $242 |
| Meloxicam | 12 | $14 |
Paid to pharmacies, not to this prescriber.
Other urology in Dallas
- Allen MoreyDallas$914K
- Vitaly MargulisDallas$555K
- Yair LotanDallas$371K
- Claus RoehrbornDallas$169K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.